RougeTx raises USD 58 million Series A led by Angelini Ventures

RougeTx raised $58 million in a Series A co-led by Kurma Partners to fund development of vascular-stabilizing small-molecule therapies. The preclinical biotech targets pericyte dysfunction, aiming to restore vascular integrity in hereditary hemorrhagic telangiectasia, an inherited bleeding disorder. Proceeds will advance lead program RTX-001 toward first-in-human trials as a potential once-daily oral treatment for HHT. Funding also supports expansion of RougeTx’s periSCOPE platform pipeline into other diseases driven by vascular instability. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kurma Partners SA published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein. (C)